ChinaBio® Daily UpdateContents
Written by Richard Daverman, PhD. I want to thank you for being a keen reader and subscriber to ChinaBio Today, but just as the biopharma landscape is changing, so are we.
For 17 years, we have brought you news on the rapidly evolving life science industry in China and the wider Asia-Pacific region through ChinaBio Today. Now, with ChinaBio Today’s editor Richard Daverman on board, we intend to continue the journey to report these deals and trends in our brand-new publication BioXconomy.
BioXconomy is the official media partner for Informa Connect Life Sciences partnering events, which now includes ChinaBio Partnering Forum and ChinaBio Investor Forum among the flagship LSX, EBD Group, and partneringONE brands.
The APAC region will become a major focus amid our year-round coverage of life sciences investment, innovation, partnerships, and business strategies within the virtual pages of BioXconomy. Along with our regular “Eyes on Asia” dealmaking round-up, we will strive to bring you an insider’s look into some of the bigger stories and rumblings within China and beyond.
ChinaBio Today will remain available as an archive, but going forward subscribe to the BioXconomy newsletter here to stay abreast of movements in Asia and beyond.
Thanks again for your continued following.
Dan Stanton
Editorial director, Informa Connect Life Sciences
Written by Richard Daverman, PhD. AstraZeneca in-licensed a preclinical small molecule lipoprotein (a) (Lp(a)) disruptor from China’s CSPC Pharma. Lp(a) is similar to low-density lipoprotein (LDL), the “bad cholesterol.” It is a type of fat in the blood that carries cholesterol, causing arterial blockages similar to low-density lipoprotein (LDL). Lp(a) hasn’t been a drug target until recently. CSPC will receive a $100 million upfront payment and could receive up to $1.9 billion in milestones plus tiered royalties. More details....
Share this with colleagues:
Written by Richard Daverman, PhD. Tokyo’s Astellas Pharma signed an option to acquire global rights for a neurology gene therapy from AviadoBio of London. The candidate, AVB-101, is an AAV-based gene therapy currently in a Phase I/II trial for patients with a frontotemporal dementia with mutations in progranulin (FTD-GRN). Astellas will invest $20 million in AviadoBio and pay $30 million in upfront payments to acquire the option. If the option is exercised, AviadoBio is eligible for up to $2.2 billion in license fees and milestones plus royalties.More details....
Share this with colleagues:
Written by Richard Daverman, PhD.
- Regor Pharma, a Shanghai-Boston biotech, received $850 million upfront from Genentech for global rights to two early-stage CDK inhibitors aimed at breast cancer;
- Kailera Therapeutics launched with a four-drug pipeline from Hengrui aimed at obesity; Keilera was formed by four US VCs who funded the startup with an initial $400 million;
- Caliway Biopharma staged a record-high IPO for a biotech company on the Taiwan Exchange, raising $206 million at a $3 billion valuation for its targeted weight loss candidate;
- Flagship Pioneering, a Cambridge, MA company, formed a collaboration with Singapore’s A*STAR to back new Singapore-based health companies;
- Hong Kong’s GenEditBio received a strategic investment from Gobi Partners GBA to develop affordable "precision DNA surgery" gene therapies for genetic diseases.
Share this with colleagues:
Written by Richard Daverman, PhD. Caliway Biopharmaceuticals IPO’d on the Taiwan Exchange (TWSE-6919) to support its portfolio of medical aesthetic and inflammatory disease candidates. The listing, which valued the company at nearly $3 billion, raised $206 million. It is a record for the largest IPO of a biopharma company in Taiwan’s history. Caliway is ready to start Phase III trials of its lead product, CBL-514, an injection that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas. More details....
Share this with colleagues:
Written by Richard Daverman, PhD.
Not a ChinaBio®Today Subscriber? Here's what you get with a paid subscription to ChinaBio® Today: - Website access to all current articles and commentary
- Full access to over 2000 archived articles on the biotech industry
ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC
| 
